Is CanSino Biologics Inc. (CASBF) a Buy, Sell, or Hold?
OTC : CASBF
CanSino Biologics Inc.
$3.145 USD
$0 (0.0%)
- Volume
- 200
- Average Volume
- 95
- Market Capitalization
- $1.1B
- P/E Ratio
- 1692.95
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $6.99
- Year Low
- $2.60
- Day High
- —
- Day Low
- —
- Payout Ratio
- -$12.32
- Current Ratio
- $4.11
Company Overview
OTC
Xue Feng Yu
Drug Manufacturers - Specialty & Generic
Healthcare
CASBF
1134
CN
USD
Liquidity Metrics
0.24
4.11
3.66
1.25
-12.32
Sales & Valuation
$1.03B
8.22
2.53
-67.55
-0.55
Profitability
$0.11
$27.15M
-0.09%
0.35%
-0.02%
-0.01%
P/E Metrics
1692.95
-59.64
-59.64
Analyst Price Target & Rating
2/5
0 Analysts
%
Financial Health Scores
2.68
5/9
$2.78B
$6.96B
$2.06B
-$61.73M
Key Metrics (TTM)
$9.11B
8.13
50.11
4.11
-0.02%
0.01%
-0.01%
-1.50%
720 days
Company Executives
| Name | Title |
|---|---|
| Xuefeng Yu | Co-Founder, Executive Chairman, Chief Executive Officer & GM |
| Jing Wang | Chief Commercial Officer, Deputy GM & Executive Director |
| Yonghui Wu | Vice President of Marketing |
| Bei Bei Gao | Accounting Supervisor |
| Dongxu Qiu | Co-Founder, Executive Vice President & Deputy GM |
| Shou-Bai Chao | Chief Operating Officer, Deputy GM & Executive Director |
| Ming Liu | Acting Head of Finance |
| Jin Cui | Board Secretary |
| Chunlin Xin | Senior Director of New Technology Department |
| Tao Zhu | Co-Founder, Deputy GM & Chief Scientific Officer |
Poll Results
No votes yet today — be the first to share your view!
About CanSino Biologics Inc. (OTC:CASBF) Stock
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vacc ... inated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. The company was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.
Frequently Asked Questions
-
What is the current CanSino Biologics Inc. (CASBF) stock price?
-
CanSino Biologics Inc.(OTC:CASBF) stock price is $3.145 in the last trading session. During the trading session, CASBF stock reached the peak price of $6.99 while $2.6 was the lowest point it dropped to. The percentage change in CASBF stock occurred in the recent session was 0.0% while the dollar amount for the price change in CASBF stock was $0.
-
CASBF's industry and sector of operation?
-
The OTC listed CASBF is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of CASBF?
-
Xuefeng Yu | Co-Founder, Executive Chairman, Chief Executive Officer & GM
Jing Wang | Chief Commercial Officer, Deputy GM & Executive Director
Yonghui Wu | Vice President of Marketing
Bei Bei Gao | Accounting Supervisor
Dongxu Qiu | Co-Founder, Executive Vice President & Deputy GM -
How many employees does CASBF have?
-
Number of CASBF employees currently stands at 1134. CASBF operates from 401-420, Biomedical Park, Tianjin, TI 300457, CN.
-
Link for CASBF official website?
-
Official Website of CASBF is: http://www.cansinotech.com
-
How do I contact CASBF?
-
CASBF could be contacted at phone #400 922 2099 and can also be accessed through its website. CASBF operates from 401-420, Biomedical Park, Tianjin, TI 300457, CN.
-
How many shares of CASBF are traded daily?
-
The average number of CASBF shares traded daily for last 3 months was 95.
-
What is the market cap of CASBF currently?
-
The market value of CASBF currently stands at $1.1B with its latest stock price at $3.145